Live in the Yes
Tirzepatide acts on GIP and GLP-1 receptors to help control insulin release and appetite
Change dose or switch peptides if there is a suboptimal response after the planned test period, usually 8 to 12 weeks, unless clinical indications dictate otherwise
Nevertheless, as the simultaneous activation of GLP-1 and GIP receptors in preclinical models results in greater WL and glucose-lowering efficacy compared to activation of each receptor alone [38,39,40], the interest for the development of unimolecular GLP-1 and GIP RA was increased, despite that this additive effect in food intake and glycaemia was not observed in some acute clinical studies [41, 42]
Because cuproptosis preferentially targets cells with high oxidative phosphorylation (OXPHOS) dependency, whereas glycolytic tumors remain relatively resistant, it exposes a distinct metabolic vulnerability in cancer and presents unique therapeutic opportunities 165,166